CD-ROM

Clinical trials

Presentation type		Track	Abstract category	Text
All Oral abstracts Poster Discussions Poster Exhibition CD-ROM		All A B C D	All Acute and early infection Acute and early infection and management of patients with acquired viral resistance Adherence in adults Adherence in children and adolescents Ageing AIDS related malignancies (KS, lymphoma, cervical and anal carcinoma) including HHV8 infection Animal Models Animal models of transmission, disease resistance and progression Antibody based vaccines Antiretroviral Therapies (strategic categories apply to resource rich and constrained settings) in Children and Adolescents Antiretroviral therapy,clinical trials and cohorts Antiretroviral treatment of people living with HIV for prevention Approaches to counselling and testing in children and caregivers Behavioural surveillance Bioinformatic analysis in drug resistance Bioinformatics analysis of viral diversity in natural history Blood, organ and tissue safety and nosocomial transmission Cellular immunity based vaccines Clinical trials Cohort studies Complementary and traditional medicines and the role of traditional healers in therapy Complications of Anti-Retroviral Therapy and Adherence in Adults and Children Correlates of immune protection Diagnosis of HIV disease Diagnostic Tools for the Immunological and Virological Monitoring of HIV Infection Disease burden – morbidity/mortality Epidemiology of HIV in people who use drugs Epidemiology of sexually transmitted infections (STI) and HIV Estimating the need for HIV treatment Estimating the size of HIV-infected and most at risk population Ethical issues in epidemiological research First line therapy Harm reduction, including reduction of unsafe injecting and other approaches Hepatitis co-infections: (including HBV, HCV) HIV counselling, testing and diagnostic strategies HIV diversity and epidemiology HIV Pathogenesis/Immune Function and Dysfunction HIV Pathogenesis/Latency and Viral Reservoirs HIV superinfections HIV Surveillance, Monitoring and Evaluation HIV tropism, dynamics and fitness HIV-1 and HIV-2 co-infections HIV-2 Host genetics of resistance and susceptibility Immune reconstitution disorders / IRIS Impact of nutrition Innate immunity responses and function in natural history of HIV infection Malaria Male and female condoms and other physical barriers Male circumcision Management of late presenters Measuring and modelling the effect and impact of other HIV prevention interventions Measuring and modelling the effect and impact of PMTCT Measuring and modelling the impact of the HIV epidemic Mechanisms of T cell depletion and dysfunction Methodological Issues and Capacity-Building in Epidemiology and Prevention Research Microbicides Monitoring and evaluation (other) Monitoring and evaluation of HIV prevention, care and treatment Mother to child transmission Mucosal immunity/defenses: responses and dysfunction Mucosal transmission Mycobacteria and TB Natural history, progression and survival Neurologic and psychiatric manifestations, including neurocognitive disorders New HIV testing and diagnostic strategies New monitoring strategies including rapid tests Non pathogenic models of SIV Non-AIDS related co-morbidities (e.g. diabetes, hypertension etc) Non-AIDS related malignancies Novel animal models for vaccine and inhibitor development Novel assays of immune responses Novel Treatment and Prevention Strategies Novel vectors and strategies Nucleic acid based HIV and SIV therapies Opportunistic infections (excluding mycobacterial) Other adverse reactions and complications of ARV therapy Other bacterial infections and malaria and parasitic infections Other complications Other Therapies Paediatric surveillance of HIV Pharmacogenomics Pharmacology, pharmacokinetics, drug formulations Population-based surveys with HIV testing Preclinical development of microbicides Pre-exposure and post-exposure prophylaxis Prevention addressing gender inequalities Prevention for men who have sex with men (MSM) Prevention for people living with HIV Prevention for people who use drugs Prevention for the general population Prevention in institutional settings e.g. workplace, school, prison, military Prevention of mother-to-child transmission Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT Research designs in epidemiology Sexually transmitted infections (STI) Simplification strategies (induction/maintenance and use of bPI monotherapy) STI prevention and control Surveillance of HIV (Youth and Adults) Surveillance systems and methods Switch studies Therapy for the heavily pre-treated patient Track B - Clinical Sciences Track C: Epidemiology and Prevention Sciences Transmission and Early Infection Tuberculosis Viral determinants of SIV pathogenesis Viral fitness and tropism assays, utility and application in clinical practice Viral resistance testing in clinical trials and practice Virus-specific cellular immunity When to start therapy
Late breakers only

Posters with this symbol have been selected by the Scientific Programme Committee for distinction based on merit.

Posters with this symbol have an e-Poster available.

CDB070 Abstract Increasing efficiency in HIV drug development: methods for stopping futile studies early S.H. Hughes1, R.L. Cuffe1, A. Lieftucht2, W.G. Nichols3 1GlaxoSmithKline, Infectious Disease Statistics, Greenford, United Kingdom, 2GlaxoSmithKline, Decision Sciences, Greenford, United Kingdom, 3GlaxoSmithKline, Infectious Diseases Medicines Development Centre, Research Triangle Park, United States CDB072 Abstract ARTEMIS: week 96 safety and efficacy of darunavir/r by gender, age and race J. Fourie1, J. Flamm2, A. Rodriguez-French3, D. Kilby4, B. Van Baelen5, V. Sekar6, L. Lavreys5 1Chronic Diseases of Lifestyle Unit, Tygerberg, South Africa, 2Kaiser Permanente Medical Group, Sacramento, United States, 3Hospital Santo Tomas, Panama City, Panama, 4University of Ottawa Health Services, Ottawa, Canada, 5Tibotec BVBA, Mechelen, Belgium, 6Tibotec Inc., Yardley, PA, United States CDB073 Abstract Gender analysis of darunavir in combination with low-dose ritonavir (600/100 mg bid): results at 48 weeks from 79 Italian centers participating to the Expanded Access Program (EAP) TMC114-C226 R. Termini1, A. Castagna2, F. Gatti3, S. Bonora4, M.P. Trotta5, P. Meraviglia6, R. Bellagamba7, G. Guaraldi8, S. Rusconi9, L. Sangiovanni10 1Janssen-Cilag SpA, Medical Affairs, Milan, Italy, 2Fondazione San Raffaele del Monte Tabor, Divisione di Malattie Infettive, Milan, Italy, 3Azienda Ospedaliera Spedali Civili di Brescia, Istituto di Malattie Infettive e Tropicali, Brescia, Italy, 4Ospedale Amedeo di Savoia, Clinica Universitaria di Malattie Infettive, Turin, Italy, 5IRCCS Ospedale Lazzaro Spallanzani, III Divisione Malattie Infettive, Rome, Italy, 6Azienda Ospedaliera Luigi Sacco, Unità Operativa Malattie Infettive II, Milan, Italy, 7IRCCS Ospedale Lazzaro Spallanzani, IV Divisione Malattie Infettive, Rome, Italy, 8Università degli Studi di Modena e Reggio Emilia, Clinica Malattie Infettive e Tropicali, Modena, Italy, 9Ospedale Luigi Sacco, Azienda Ospedaliera e Polo Universitario, Clinica Universitaria Malattie Infettive e Tropicali, Milan, Italy, 10IRCCS Policlinico S. Matteo, Divisione di Malattie Infettive e Tropicali, Pavia, Italy